What's up with the additional 5 million share offering @ $4.80. They just had a HUGE offering. Seems bogus to me.
Check out SSR they just came out with an email report on OXBT, pretty interesting report. If you're a trader you should sign up to their free newsletter regardless. Their last downgrade was on PLUG, next day it tanked 40%...LOL
Depends how many shares you use to manipulate the price..10 cents can be a lot of money..
Like the volume increase in the last 2 days. Back in at 4.49. This drug is approved already in 50 countries. Stock will be over $10 by eoy imo.
By Zacks, today
Oxygen Biotherapeutics, Inc. (OXBT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at OXBT given that, according to its RSI reading of 29.80, it is now in oversold territory.
What is RSI?
RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.
Yet, OXBT’s low RSI value isn’t the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to Oxygen Biotherapeutics’s earnings consensus.
Over the past two months, investors have seen 1 earnings estimate revision move higher, compared with just none lower, at least when looking at the key current year time frame. And the consensus estimate for OXBT has also been on an upward trend over the past 60 days, as estimates have risen from -$0.87/share two months ago to just -$0.63/share right now.
If this wasn’t enough, Oxygen Biotherapeutics also has a Zacks Rank #2 (Buy) which puts it into rare company among its peers. So, given all of these factors, investors may want to consider getting in on this stock now (or holding on), as there are some favorable trends that could bubble up for this stock before long.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Anyone who read the reports would. The company is not going to be 10 people for very long. If you go review their news on this site you will find where they take about it when they discuss the sale of first group of shares. I would waste a lot of time getting overly worried. It's not a big deal. People expect to be paid. Paying them with shares rather than cash can work to the companies benefit.
$ 20 millionin compensation for a company of 10 people ? Just after a $50 million dollar offering? Come on, no one was anticipating that.